Leadership

KineMed is led by a talented team of seasoned leaders with a unique combination of expertise in medicine, pharmacology, drug discovery and development, and the creation and financing of successful biomedical enterprises. This combination of scientific and business expertise allows KineMed to pursue academic and industry-based collaborations as well as its internal drug development programs for expedited value creation.

Members of the KineMed management teams bring a wealth of hands-on experience in drug development to KineMed as well as a validated approach to the application of translational medicine (TM) and personalized medicine (PM).

• David M. Fineman
  Chairman, President & Chief Executive Officer
• Marc K. Hellerstein, M.D., Ph.D.
  Co-Founder, Chairman of the Scientific Advisory Board
• Brent Vaughan, M.B.A.
  Chief Business Officer
• Alexander Glass, Ph.D.
  Executive Vice President, Instrumentation
• Koenraad Wiedhaup, Ph.D.
  Consultant and Advisor
• Scott Turner, Ph.D.
  Vice President, Cardiometabolic & Fibrotic Diseases and Research Operations
• Cyril De Colle, Ph.D.
  Vice-President, Neuroscience
• Karen Carothers, C.P.A.
  Vice-President, Finance
• James Burden, J.D.
  Corporate Counsel
• Michael Glembourtt, M.B.A.
  Acting Vice President, Project Management & Pre-clinical Development